Home › Companies › 4D MOLECULAR THERAPEUTICS INC. › 2023-2024
At 4D MOLECULAR THERAPEUTICS INC.'s shareholder meeting held May 21, 2024, in the 2023-2024 proxy season, 58 asset managers reported how they voted on 2 ballot items in their SEC Form N-PX filings, covering 342 separate fund positions. On the most widely held item on that ballot — Election of one Class I director to hold office until the 2027 Annual Meeting of Stockholders… — FOR was 82% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: 4D MOLECULAR THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 24, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and 4D MOLECULAR THERAPEUTICS INC.’s Form 8-K, filed May 24, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 21, 2024: 2 items on 4D MOLECULAR THERAPEUTICS INC.’s Form 8-K, filed May 24, 2024: 1 approved · 1 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore 4D MOLECULAR THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are 4D MOLECULAR THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David Kirn, M.D. | 35,630,613 | -- | -- | 7,849,441 | 1,574,659 | 82% | Not verified | — |
| 2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 | 45,032,000 | 21,052 | 1,661 | -- | -- | 99.9% | Approved | — |
Source: 4D MOLECULAR THERAPEUTICS INC., Form 8-K, filed with the SEC on May 24, 2024 — read the filing on EDGAR.
Each item below shows how the 58 asset managers that disclosed a 4D MOLECULAR THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of one Class I director to hold office until the 2027 Annual Meeting of Stockholders or until their successor is elected: David Kirn, M.D.
4D MOLECULAR THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Kirn, M.D.”): 35,630,613 for, 7,849,441 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 7,737,987 for, 61 against, 1,875,675 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,283,755 | 0 | 0 | 0 | For |
| BlackRock | 1,972,974 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 1,036,428 | Withhold |
| Fidelity | 910,042 | 0 | 0 | 0 | For |
| State Street | 790,281 | 0 | 0 | 11,684 | For |
| MUTUAL FUND SERIES TRUST | 776,114 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 428,560 | Withhold |
| Charles Schwab | 302,205 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 141,735 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 130,684 | Withhold |
| TIAA | 107,367 | 0 | 0 | 0 | For |
| Equitable | 105,244 | 0 | 0 | 0 | For |
| SEI | 83,359 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 75,722 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,800 | 0 | 0 | 19,167 | Mixed |
| Northern Trust | 39,525 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 35,109 | Withhold |
| ProShares | 0 | 0 | 0 | 34,634 | Withhold |
| First Trust | 0 | 0 | 0 | 29,895 | Withhold |
| Pacific Life | 27,985 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 20,527 | Withhold |
| New York Life | 8,580 | 0 | 0 | 11,554 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 20,020 | Withhold |
| Global X | 17,635 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 15,849 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
4D MOLECULAR THERAPEUTICS INC.’s own tally for this item (“2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024”): 45,032,000 for, 21,052 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 9,612,343 for, 1,380 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,283,755 | 0 | 0 | 0 | For |
| BlackRock | 1,972,974 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,036,428 | 0 | 0 | 0 | For |
| Fidelity | 910,042 | 0 | 0 | 0 | For |
| State Street | 800,585 | 1,380 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 776,114 | 0 | 0 | 0 | For |
| Dimensional | 428,560 | 0 | 0 | 0 | For |
| Charles Schwab | 302,205 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 141,735 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 130,684 | 0 | 0 | 0 | For |
| TIAA | 107,367 | 0 | 0 | 0 | For |
| Equitable | 105,244 | 0 | 0 | 0 | For |
| SEI | 83,359 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 75,722 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,967 | 0 | 0 | 0 | For |
| Northern Trust | 39,525 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 35,109 | 0 | 0 | 0 | For |
| ProShares | 34,634 | 0 | 0 | 0 | For |
| First Trust | 29,895 | 0 | 0 | 0 | For |
| Pacific Life | 27,985 | 0 | 0 | 0 | For |
| Goldman Sachs | 20,527 | 0 | 0 | 0 | For |
| New York Life | 20,134 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 20,020 | 0 | 0 | 0 | For |
| Global X | 17,635 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 15,849 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,778,127 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.59% |
| 2 | BlackRock | 3.96% |
| 3 | JANUS INVESTMENT FUND | 2.08% |
| 4 | Fidelity | 1.83% |
| 5 | State Street | 1.61% |
| 6 | MUTUAL FUND SERIES TRUST | 1.56% |
| 7 | Dimensional | 0.86% |
| 8 | Charles Schwab | 0.61% |
| 9 | MERIDIAN FUND INC | 0.28% |
| 10 | Direxion Shares ETF Trust | 0.26% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Keel Point, LLC | <0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BVF PARTNERS L P/IL | 9.31% | 13G |
| RA Capital Management, L.P. | 9.17% | 13G |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 8.53% | DEF14A |
| Goldman Sachs | 8.29% | 13F |
| Biotechnology Value Fund, L.P. | 8.05% | DEF14A |
| BlackRock | 7.77% | 13F |
| Vanguard Group | 5.17% | 13F |
| JANUS HENDERSON GROUP PLC | 4.52% | 13G |
| State Street | 4.38% | 13F |
| David Kirn, M.D. | 3.33% | DEF14A |
Percentages above are of 49,778,127 shares outstanding, as reported by 4D MOLECULAR THERAPEUTICS INC. on its Form 10-K dated February 23, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D MOLECULAR THERAPEUTICS INC.’s 10-K dated February 23, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
4D MOLECULAR THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “4D MOLECULAR THERAPEUTICS (FDMT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/4d-molecular-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.